HC Wainwright Has Positive Outlook for ABEO FY2024 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($1.16) per share for the year, up from their prior estimate of ($1.26). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

A number of other equities analysts have also weighed in on ABEO. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday.

Abeona Therapeutics Stock Up 6.3 %

Shares of NASDAQ:ABEO opened at $6.41 on Wednesday. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $278.64 million, a P/E ratio of -2.38 and a beta of 1.52. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The stock’s fifty day simple moving average is $6.24 and its 200-day simple moving average is $5.32.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Rosalind Advisors Inc. purchased a new stake in Abeona Therapeutics during the second quarter worth approximately $7,420,000. Renaissance Technologies LLC lifted its holdings in shares of Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics during the 2nd quarter worth $1,732,000. abrdn plc increased its holdings in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Finally, Western Standard LLC raised its position in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after purchasing an additional 110,998 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.